Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia

Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia

Background: Oestrogen receptor positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer (BC) is the most frequently diagnosed BC subtype. Combinations of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with anti-oestrogen therapy have led to improved survival compared with a...

Full description

Bibliographic Details
Main Authors: Jia Li Low, Elaine Lim, Lavina Bharwani, Andrea Wong, Karmen Wong, Samuel Ow, Siew Eng Lim, Matilda Lee, Joan Choo, Joline Lim, Gloria Chan, Robert John Walsh, Vaishnavi Muthu, Natalie Ngoi, Wanqin Chong, Sing Huang Tan, Soo Chin Lee
Format: Article
Language:English
Published: SAGE Publishing 2022-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221139678

Internet

https://doi.org/10.1177/17588359221139678

Similar Items